A Phase 1, Randomized, Open-label, Single Dose, 2-treatment Arm (200 μg and 800 μg), 4-way Crossover Study in Healthy Participants Aged 18 to 55 to Compare the Pharmacokinetics of Salbutamol Administered Via Metered Dose Inhalers Containing Propellants HFA-152A (Test) and HFA-134A (Reference)
Latest Information Update: 17 Dec 2024
At a glance
- Drugs Salbutamol (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors GSK
Most Recent Events
- 13 Dec 2024 Status changed from active, no longer recruiting to completed.
- 05 Nov 2024 Planned End Date changed from 27 Sep 2024 to 25 Oct 2024.
- 05 Nov 2024 Planned primary completion date changed from 13 Sep 2024 to 25 Oct 2024.